Funded Biotechnology Startups in Baltimore
The largest disclosed round in the 21 Baltimore biotechnology entries is Delfi Diagnostics’ $34M on 2025-12-18, and it sits far above the rest of the discl…
The largest disclosed round in the 21 Baltimore biotechnology entries is Delfi Diagnostics’ $34M on 2025-12-18, and it sits far above the rest of the disclosed amounts in this slice (the next-largest disclosed rounds are $35M for AsclepiX Therapeutics in 2020 and $31M for Vita Therapeutics in 2022, but within the 2024–2025 window the top disclosed figure is $15M from Sonavex on 2024-10-24). Two temporal clusters stand out: several rounds concentrate in October 2024 (Sonavex on 2024-10-24 for $15M, Previse on 2024-10-22 for $2M, Emit Imaging on 2024-10-03 for $5M), and a different cluster appears in August 2023 (Kalocyte and Melatech, both with $10K on 2023-08-23). Stage labeling is also uneven, with “Series Unknown” appearing 9 times and “undisclosed” amounts appearing 2 times (b.well Connected Health on 2025-01-13 and Catalio Capital Management on 2023-10-17). Date coverage runs from 2020-06-11 (Glyscend, $21M) through 2025-12-18, with the most recent entry being Delfi Diagnostics.
Most recent rounds
21 shownRelated listings
Frequently asked
What stands out as an outlier on deal size, and does it change the shape of the distribution?
For the 21 rows shown, disclosed amounts reach a peak at Delfi Diagnostics’ $34M (2025-12-18). Several other disclosed rounds are in the tens of millions as well (AsclepiX Therapeutics $35M on 2020-06-24; Vita Therapeutics $31M on 2022-10-12), while many entries are far smaller, including repeated $10K rounds for Kalocyte and Melatech on 2023-08-23.
Are there tight time windows where multiple funding events cluster?
Yes. October 2024 includes three entries within about three weeks: Sonavex ($15M on 2024-10-24), Previse ($2M on 2024-10-22), and Emit Imaging ($5M on 2024-10-03). A second concentration appears on 2023-08-23 with Kalocyte ($10K) and Melatech ($10K).
How much of the list is hard to benchmark because of missing or undisclosed round details?
Stage and amount disclosure are incomplete in this slice: 9 of 21 entries are labeled “Series Unknown,” and 2 entries show an “undisclosed” amount (b.well Connected Health on 2025-01-13 and Catalio Capital Management on 2023-10-17). That means the most comparable cross-round analysis relies more on labeled rounds like Sonavex ($15M, Series A on 2024-10-24) than on the unknowns.
Which stages appear most often, and do they cluster around particular years?
Beyond “Series Unknown” (9 entries), the clearer stage labels here include Seed (Somnair $4M on 2025-07-07; Irazu Oncology $500K on 2025-03-05; NKA Bio $30K on 2023-04-03) and Series A (Sonavex $15M on 2024-10-24; Rapafusyn Pharmaceuticals $28M on 2024-06-20). Larger labeled rounds also appear outside 2024–2025, such as Vita Therapeutics’ Series B $31M on 2022-10-12.
Do recent months (e.g., the last ~90 days in the table) show a consistent funding pattern?
In the most recent segment of the table, 2025-12-18 (Delfi Diagnostics, $34M) is the only entry after mid-year. The next recent entries are in 2025-07 through 2025-03 (Somnair $4M on 2025-07-07; Novel Microdevices $630K on 2025-06-10; Irazu Oncology $500K on 2025-03-05), which contrasts with the much larger disclosed figure on 2025-12-18.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.